Clinical
RSSArticles
-
Mavacamten Capsules (Camzyos)
Mavacamten can be prescribed to adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
In a study of human papillomavirus (HPV) vaccination, researchers evaluated cancer protection over up to 11 years of follow-up. During this time, the authors noted 100% vaccine efficacy at preventing HPV-associated cancers.
-
Regarding Exercise Capacity Past Age 75 Years, What Is Normal?
A group of researchers delivered results that could help inform clinicians about the expected exercise test performance of older patients.
-
Recommendations Regarding Physical Activity to Delay Death
Using objective measurements of exercise intensity, researchers approximated 110,000 U.S. deaths/year could be prevented by a 10-minute daily increase in moderate-to-vigorous physical activity in adults age 40-85 years.
-
Beware the Cardiovascular Risks Associated with Thyroid Hormone Replacement Therapy
Thyroid levels outside the euthyroid range have been associated with higher cardiovascular risk in patients taking thyroid hormone to treat hypothyroidism. In this study, a higher cardiovascular mortality rate was associated with exogenous hyperthyroidism and exogenous hypothyroidism.
-
Long COVID Patients Report Symptoms 15 Months Later
Brain fog, dizziness, and more side effects can linger for many months after initial SARS-CoV-2 infection.
-
Omega-3 May Help Lower Blood Pressure
A research review revealed consuming about 2 or 3 grams of the fatty acid per day showed benefit.
-
Young People Show Support for Social Determinants of Health Screening
Members of Generation Z appear willing to engage with clinicians about food security, housing, education, and more.
-
Did You See Both ECG Findings?
The ECG in the figure was obtained from an older man with new chest pain. There are two principal ECG findings on this tracing. Do you see both?
-
Oteseconazole Capsules (Vivjoa)
The FDA has approved the first drug to reduce recurrent vulvovaginal candidiasis.